News

Intergalactic Therapeutics, based in Cambridge, MA, announced its closing after less than 2 years since the company's launch in 2021.

Veena Raiji, MD, MPH, spoke with our team about long-term outcomes of eyes requiring IOP-lowering medication in the PALADIN trial at the 2023 ASRS annual meeting.

Veena Raiji, MD, MPH, spoke with our team about long-term outcomes of eyes requiring IOP-lowering medication in the PALADIN trial at the 2023 ASRS annual meeting.

Choroideremia shares traits with retinitis pigmentosa (RP). Both diseases are caused by underlying inherited gene defects and result in the death of photoreceptors within the retina.

The US and German collaborative study found performing vitrectomy with silicone oil tamponade to manage postoperative endophthalmitis led to a significant improvement in visual acuity (VA) and had a low complication rate.

The investigators explored the effects of the following covariates on development of AMD: sex, ethnicity, smoking history, fluoxetine use, obesity, diabetes mellitus, and hypertension.

Influencers on TikTok claim the vegetable oil promotes eye health. However, ophthalmologists say the risks aren't worth any minimal benefits.

Faricimab could lower treatment burden for patients compared to aflibercept

Canadian and Australian ophthalmologists and optometrists are looking ahead at the impact increased wildfire smoke can have on the ocular surface.

The partnership will drive Kiora's development of KIO-301, a small molecule designed to restore vision in patients with later-stage retinal degeneration.

In addition to the educational offerings, the program offers opportunities for relaxation and spiritual and family-building events.

Novel concept: inner choroid/outer retina neurovascular unit

IZERVAY is expected to be available in the United States within 2 to 4 weeks.

Of the 484 hospitals, 22 are named to the national Honor Roll for ranking in one or more of the specialties that US News evaluates.

At the 2023 ASRS annual meeting in Seattle, Washington, Michael Singer, MD, spoke with our team about the Starlight Study, which is an optogenetic study looking at patients who had Stargardt disease.

Michael Singer, MD, spoke with our team about the Starlight Study, an optogenetic study looking at patients who had Stargardt's disease at the 2023 ASRS annual meeting. At the meeting, Nanoscope Therapeutics Inc presented key results from its STARLIGHT Phase 2 clinical trial.

OSC-01 is a novel, high concentration preservative-free topical OPTIREACH formulation of dexamethasone.

Aleksandra Rachiskaya, MD, a member of the Modern Retina advisory board, spoke with our team about time to fluid control with faricimab arms complete compared to aflibercept in recent studies at the 2023 ASRS annual meeting.

The Summit will inspire and enable attendees to achieve their goals via a multi-pronged approach.

The gene therapy company announces its closure less than 2 years after the company launch in 2021.

Aleksandra Rachiskaya, MD, spoke with our team about time to fluid control with faricimab arms complete compared to aflibercept at the 2023 ASRS annual meeting.

Take a look at a review of the highlights and hottest stories from Ophthalmology Times during the week of July 30, 2023.

According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials.

According to the company, the solution slowed the loss of photoreceptors and disease progression as early as six months.

Nancy Lurker, spoke with our team about the subgroup analyses of the Phase 1 DAVIO Trial of EYP-1901 at the 2023 ASRS annual meeting.